Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476994 · ClinicalTrials.gov registry record · Phase 4
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion
A Phase 4 study, sponsored by Baxter Healthcare Corporation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02476994 is a Phase 4 study that was terminated before completion, run by Baxter Healthcare Corporation. The registered enrollment target is 1 participants.
The verdict
NCT02476994, a Phase 4 study, was terminated before completion, sponsored by Baxter Healthcare Corporation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy of using Clinolipid in a pediatric population.
Interventions
- DRUG Intralipid
- DRUG Clinolipid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02476994
The ClinicalTrials.gov registry entry for NCT02476994 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intralipid is the first listed.
NCT02476994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02476994 about?
NCT02476994 is a clinical study titled "Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion". This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy o...
What is the current status of trial NCT02476994?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2015-05. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02476994?
The interventions under investigation include: Intralipid (DRUG), Clinolipid (DRUG).
Who is sponsoring clinical trial NCT02476994?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.